Replicate Study design for Brazil [Regulatives / Guidelines]

posted by weidson – Brazil, 2018-05-22 20:51 (888 d 23:32 ago) – Posting: # 18799
Views: 1,664

Dear balakotu

The ANVISA have adopted the EMA's Approach. However, for you use this approach you need to convince them that their drug is highly variable. I hope I have helped you.


Best Regards
Weidson C. de Souza


Edit: Post moved. [Helmut]

Complete thread:

Activity
 Admin contact
21,179 posts in 4,414 threads, 1,474 registered users;
online 5 (0 registered, 5 guests [including 5 identified bots]).
Forum time: Tuesday 19:24 CET (Europe/Vienna)

No computer has ever been designed
that is ever aware of what it’s doing;
but most of the time, we aren’t either.    Marvin Minsky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5